CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Broken String Biosciences
Company Type: Therapeutics
Main focus: Development of bioinformatic tools to assess genome-editing modification
Company stage: Pre-clinical
Diseases:
Genome-editing tool:
Funding stage: Series A
Location: Cambridge, UK
Website: https://www.brokenstringbio.com/
Pipeline:
Broken String Biosciences is building a technology platform that accelerates the characterisation of novel genome-editing technologies, with the aim of unlocking the next wave of cell & gene therapies. The company's vision is a future where cell & gene therapies are safer, more efficient, and affordable for patients. Starting with its DNA break mapping technology INDUCE-seq™, Broken String Biosciences' data-driven platform reveals precisely how genome editors interact with and alter our genomes. Broken String Biosciences is backed by Illumina and Tencent and is based at the Wellcome Genome Campus, Cambridge, UK.
